- Stocks
- Healthcare
- NASDAQ: AZN

Price (delayed)

$78.135

Market cap

$242.24B

P/E Ratio

38.11

Dividend/share

$1.45

EPS

$2.05

Enterprise value

$268.95B

AstraZeneca plc is a British-Swedish multinational pharmaceutical and biotechnology company with its headquarters at the Cambridge Biomedical Campus in Cambridge, England.

AZN's net income is up by 35% year-on-year and by 6% since the previous quarter

Astrazeneca's EPS has increased by 35% YoY and by 7% QoQ

AZN's price to earnings (P/E) is 72% lower than its 5-year quarterly average of 138.9 but 11% higher than its last 4 quarters average of 34.9

AZN's equity is up by 4.6% year-on-year but it is down by 4.3% since the previous quarter

AZN's debt is up by 21% since the previous quarter and by 10% year-on-year

What are the main financial stats of AZN

Market
Valuations
Earnings

Shares outstanding

3.1B

Market cap

$242.24B

Enterprise value

$268.95B

Price to earnings (P/E)

38.11

Price to book (P/B)

6.47

Price to sales (P/S)

5.08

EV/EBIT

29.54

EV/EBITDA

18.88

EV/Sales

5.65

Revenue

$47.61B

EBIT

$9.11B

EBITDA

$14.25B

Free cash flow

$8.23B

Per share
Balance sheet
Liquidity

EPS

$2.05

Free cash flow per share

$2.66

Book value per share

$12.08

Revenue per share

$15.37

TBVPS

$14.04

Total assets

$102.29B

Total liabilities

$64.79B

Debt

$34.55B

Equity

$37.45B

Working capital

-$3.31B

Debt to equity

0.92

Current ratio

0.89

Quick ratio

0.69

Net debt/EBITDA

1.88

Margins
Efficiency
Dividend

EBITDA margin

29.9%

Gross margin

82%

Net margin

13.3%

Operating margin

18.4%

Return on assets

6.4%

Return on equity

16.8%

Return on invested capital

24.9%

Return on capital employed

12.4%

Return on sales

19.1%

Dividend yield

1.86%

DPS

$1.45

Payout ratio

70.7%

How has the Astrazeneca stock price performed over time

Intraday

-1.39%

1 week

1.3%

1 month

-1.83%

1 year

15.96%

YTD

16.01%

QTD

0.19%

How have Astrazeneca's revenue and profit performed over time

Revenue

$47.61B

Gross profit

$39.03B

Operating income

$8.76B

Net income

$6.33B

Gross margin

82%

Net margin

13.3%

AZN's operating income has surged by 61% year-on-year and by 7% since the previous quarter

The operating margin has grown by 48% YoY and by 2.8% from the previous quarter

AZN's net income is up by 35% year-on-year and by 6% since the previous quarter

AZN's net margin is up by 24% year-on-year and by 2.3% since the previous quarter

What is Astrazeneca's growth rate over time

What is Astrazeneca stock price valuation

P/E

38.11

P/B

6.47

P/S

5.08

EV/EBIT

29.54

EV/EBITDA

18.88

EV/Sales

5.65

AZN's price to earnings (P/E) is 72% lower than its 5-year quarterly average of 138.9 but 11% higher than its last 4 quarters average of 34.9

Astrazeneca's EPS has increased by 35% YoY and by 7% QoQ

The stock's price to book (P/B) is 17% more than its last 4 quarters average of 5.6 but 10% less than its 5-year quarterly average of 7.3

AZN's equity is up by 4.6% year-on-year but it is down by 4.3% since the previous quarter

The stock's price to sales (P/S) is 10% more than its last 4 quarters average of 4.7 and 5% more than its 5-year quarterly average of 4.9

Astrazeneca's revenue has increased by 9% YoY and by 3.9% QoQ

How efficient is Astrazeneca business performance

Astrazeneca's return on invested capital has surged by 64% YoY and by 4.2% QoQ

Astrazeneca's return on sales has surged by 50% YoY and by 2.7% QoQ

The return on assets is up by 31% year-on-year and by 4.9% since the previous quarter

The company's return on equity rose by 28% YoY and by 6% QoQ

What is AZN's dividend history

DPS

$1.45

Dividend yield

1.86%

Payout ratio

70.7%

Recent dividends

How did Astrazeneca financials performed over time

The company's total assets is 58% higher than its total liabilities

The quick ratio rose by 11% since the previous quarter

AZN's current ratio is up by 9% from the previous quarter

AZN's debt is 8% smaller than its equity

AZN's debt to equity is up by 26% since the previous quarter and by 4.5% year-on-year

AZN's debt is up by 21% since the previous quarter and by 10% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.